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Abstract Our aim was to evaluate real-world safety and
effectiveness in a 6-month postmarketing surveillance
study covering all Japanese patients with rheumatoid
arthritis (RA) who received etanercept during a 2-year
period. Data for 13,894 patients (1334 sites) enrolled
between March 2005 and April 2007 were collected.
Adverse events (AEs) and serious adverse events (SAEs)
were reported in 4336 (31.2%) and 857 (6.2%) patients,
respectively. The most frequent AEs were injection site
reactions (n = 610, 4.4%) and rash (n = 339, 2.4%),
whereas pneumonia (n = 116, 0.8%) and interstitial lung
disease (n = 77, 0.6%) were the most frequent SAEs.
Signiﬁcant improvement in the proportion of patients with
a good European League Against Rheumatism (EULAR)
response was observed from week 4 (17.6%) to week 24
(31.6%) (p\0.001); 84.3% of patients had good or
moderate EULAR responses at week 24. The percentage of
patients achieving remission increased signiﬁcantly from
week 4 (9.3%) to week 24 (18.9%) (p\0.001). Patients
with early moderate RA were less likely to experience
SAEs and were more likely to achieve remission compared
with patients with more severe disease. The safety and
effectiveness of etanercept was demonstrated in Japanese
patients in one of the largest observational trials conducted
thus far in RA patients treated with biologics.
Keywords DAS28  Etanercept  Postmarketing
surveillance study  Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA), a chronic inﬂammatory disease
affecting joints and extra-articular tissues, is associated
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DOI 10.1007/s10165-010-0406-3with increased pain, deterioration of physical function, and
decreased life expectancy [1, 2]. Achievement of disease
remission is considered a realistic and crucial goal for
patients with RA, as reﬂected by current treatment guide-
lines and recommendations of the European League
Against Rheumatism (EULAR), the American College of
Rheumatology (ACR), and others [3–5]. The modiﬁed
disease activity score (DAS28) [6] is a validated 28-joint
instrument that measures joint tenderness and/or swelling
and can accurately evaluate the status of disease activity
and the efﬁcacy of treatment. Because of its reliability in
monitoring and deﬁning disease activity and remission, the
DAS28 is commonly used in RA trials; it has also been
endorsed by the EULAR working group recommendations
for management of RA [5, 7].
Recent randomized clinical trials have demonstrated the
efﬁcacy and safety proﬁle of RA treatments that function as
antagonists of tumor necrosis factor alpha (TNF-a), either
as monotherapy or combined with methotrexate [7–12]. In
general, these treatment regimens were effective at reduc-
ing disease activity, achieving remission, and preventing
joint destruction in patients with RA. However, most of the
data describing efﬁcacy and safety for RA treatments come
from late-phase clinical trials or national databases.
Inclusion criteria for the studies are not always reﬂective of
treatment in a real-world environment. Large well-
designed phase 3 trials generally provide useful patient
outcomes data, but these studies may not adequately deﬁne
the true safety and effectiveness of a drug outside the
clinical research setting.
As one of the conditions of approval of etanercept in
Japan, the Pharmaceutical and Medical Device Agency
(PMDA) requested that Wyeth (now integrated into Pﬁzer
as of October 2009) conduct surveillance to conﬁrm the
safety and effectiveness of etanercept in Japanese patients
in the clinical setting after the drug was marketed. To
comply with this request, we performed a postmarketing
surveillance (PMS) study that registered all Japanese RA
patients treated with etanercept at the participating study
sites for the survey period. Etanercept is a fully human
soluble TNF-a receptor fusion protein with demonstrated
efﬁcacy against RA in patients not adequately responding
to disease-modifying antirheumatic drugs (DMARDs) such
as methotrexate [13, 14]. Etanercept has shown superior
efﬁcacy to methotrexate in patients with RA [15], and the
combination of etanercept plus methotrexate was superior
to either monotherapy alone [16]. The goal of this PMS
study was to evaluate the real-world safety and effective-
ness of etanercept for a large Japanese patient population
receiving etanercept for the treatment of RA. A previous
interim analysis comprising data for 7091 of the registered
patients reported that etanercept was effective with no new
safety signals [17]. This report covers nearly 14,000
Japanese patients with RA registered to the PMS study
from 2005 to 2007.
Patients, materials, and methods
Patients
Between March 2005 and April 2007, all Japanese patients
with RA from 1334 sites were enrolled in a 6-month PMS
study of etanercept use (NCT00503503). Patient eligibility
for treatment with etanercept was based on the Japan
College of Rheumatology treatment guidelines [18].
Brieﬂy, etanercept was indicated for patients with RA who
were previously treated with DMARDs (e.g., methotrexate,
salazosulfapyridine, or bucillamine) for [3 months, and
had C6 tender joints, C6 swollen joints, and erythrocyte
sedimentation rate (ESR) C28 mm/h or C-reactive protein
(CRP) levels C2.0 mg/dL [17]. Patients had a low risk for
opportunistic infections, deﬁned as white blood count
C4000/mm
3, peripheral blood lymphocyte count C1000/
mm
3, and negative serum b-D-glucan. Mandatory chest
radiographs and tuberculin tests were conducted before
initiation of treatment. Information on age, sex, comor-
bidity, Steinbrocker radiographic stage [19], Steinbrocker
functional class [19], duration of RA, smoking history,
previous and concomitant use of glucocorticoids, and
concomitant use of DMARDs (including methotrexate)
was collected. Also, ESR and CRP levels were assessed.
Etanercept 10 or 25 mg was administered subcutaneously
twice weekly, with the dose determined by the prescribing
physician. After an initial 1-month training period, patients
were allowed to self-inject etanercept.
The PMS protocol was reviewed and approved by the
Japanese Ministry of Health, Labor, and Welfare. Regis-
tration was conducted centrally at the time of treatment
initiation. Data collection was performed through an elec-
tronic data capture system, the Internet, or hardcopy case
report forms, and medical representative staff members
from Wyeth and Takeda Pharmaceutical Company visited
sites periodically to collect additional data as required.
Assessments
All patients were assessed for safety every 2 weeks. Safety
evaluations included all events occurring B24 weeks after
the ﬁrst etanercept dose and B30 days after the last dose.
All adverse events (AEs) were reported. Safety data were
coded with preferred terms from the Medical Dictionary
for Regulatory Activities [20]. All AEs, serious AEs
(SAEs), adverse drug reactions (ADRs; noxious and
unintended responses deemed to be related to the treat-
ment), and serious ADRs, including infection, were deﬁned
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tripartite harmonised guideline [21]. Particular attention
was paid to the occurrence of infections, especially tuber-
culosis, pneumonia, Pneumocystis jiroveci pneumonia,
cytomegalovirus infection, and sepsis and to speciﬁc
important ADRs that included malignant neoplasm,
demyelination, congestive heart failure, injection site
reaction, and lupus. Safety information was independently
evaluated by the Japan College of Rheumatology PMS
committee.
Treatment effectiveness was measured monthly using
the EULAR response criteria [22] and the DAS28 [6]. The
DAS28 is divided into 4 categories: remission (DAS28
\2.6), low disease activity (DAS28 C2.6 and B3.2),
moderate disease activity (DAS28 [3.2 and B5.1), and
high disease activity (DAS28[5.1). A good response was
deﬁned as a DAS28 improvement from baseline of [1.2
and a DAS28 of B3.2 during follow-up. Patients with score
improvements of B0.6 or those with improvements
between 0.6 and 1.2 plus a DAS28 of[5.1 during follow-
up were deﬁned as nonresponders. Moderate responders
were those with DAS28 improvements from baseline
between 0.6 and 1.2 plus a DAS28 of B5.1 during follow-
up. Treatment was considered to be effective in patients
with moderate or good DAS28 responses. General health
status was measured using a patients’ visual analog scale
(100 being the worst they can imagine, 0 being the best
they can imagine), and duration of morning stiffness was
also assessed.
Statistical analysis
Missing data were processed using the last-observation-
carried-forward method, except for baseline values, which
were not carried forward. The v
2 or t-test was used to
compare differences in baseline values between men and
women. The t-test was used to compare DAS28 differences
between baseline and weeks 4 and 24; v
2tests were used to
compare differences in EULAR response rates, and
Cochran-Armitage tests were used to examine evidence of
trends in response rates. Cox proportional hazard models
were used to estimate the inﬂuence of multiple variables on
the occurrence of serious infections (AEs). These variables
included the confounders assessed at baseline: age, sex,
concomitant methotrexate use, concomitant glucocorticoid
use, history of infectious disease, history of tuberculosis,
presence of any comorbidities, Steinbrocker functional
class, and duration of RA. A total of 1274 patients with
missing data [duration of RA (n = 1267) and other
(n = 7)] were excluded from the Cox proportional hazard
models. We also used multiple logistic regression models
to estimate the effect of variables on the likelihood of
achieving remission. Patients who had missing DAS28 data
at either baseline or at 24 weeks, a DAS28 value of\2.6 at
baseline, or missing data for other adjustment factors were
excluded from these models. Furthermore, we used Cox
proportional hazard models and multiple logistic regression
models to examine the combined effects of multiple risk
factors on the occurrence of serious infections and the
likelihood of achieving remission, respectively. The hazard
ratio or odds ratio and the 95% conﬁdence interval (CI) for
each of the combined factors after adjustment for major
confounders and the combined effect relations with num-
bers of factors were further explored by trend tests. All
statistical analyses were performed using SAS
 software
version 8.2 (SAS Institute, Cary, NC, USA). Two-sided
P values of\0.05 were considered statistically signiﬁcant.
Results
Patients
A total of 13,894 patients treated with etanercept com-
pleted the 24-week study (Table 1). The majority of
patients were women (n = 11,314; 81.4%). Mean ± SD
patient age was 58.1 ± 13.1 years; most patients (78.3%)
were aged [50 years (more than one half were aged
[60 years), and the mean ± SD patient weight was
53.2 ± 10.1 kg. About 40% of patients had a disease
duration of [10 years. Concomitant use of DMARDs/
biologics was 74.0% (n = 10,276) and that of methotrexate
was 55.9% (n = 7768). The most commonly used etaner-
cept dose regimen (76.1%; n = 10,578) was 50 mg per
week (i.e., 25 mg twice weekly). Previous use of gluco-
corticoid was 83.4% (n = 11587) and previous use of
inﬂiximab was 13.5% (n = 1878). Additionally, 57.1% of
patients had comorbidities, including 877 patients (6.3%)
with a medical history of tuberculosis. Signiﬁcant differ-
ences were observed between men and women in most
demographic characteristics, including age, weight, disease
duration, Steinbrocker stage and class, history of con-
comitant medical conditions, comorbidities, concomitant
use of methotrexate, and prior glucocorticoid use
(Table 1). A total of 11,615 (83.6%) patients completed
24 weeks of therapy, with 2309 patients (16.6%) discon-
tinuing during the 24-week period. Reasons for stopping
treatment were AEs (7.6%, n = 1049), lack of treatment
effectiveness (2.6%, n = 368), refusal of treatment for
economic reasons (1.5%, n = 212), moved to another
hospital (1.6%, n = 222), and other (3.3%, n = 458).
Safety
As shown in Table 2, AEs and SAEs were reported in 4336
(31.2%) and 857 (6.2%) patients, respectively. The most
Mod Rheumatol (2011) 21:343–351 345
123frequently observed AEs were injection site reaction
(n = 610, 4.4%), rash (n = 339, 2.4%), and abnormal
hepatic function (n = 328, 2.4%). Pneumonia was the most
frequently reported SAE (n = 116, 0.8%), followed by
interstitial lung disease (n = 77, 0.6%), and pyrexia
(n = 40, 0.3%). In total, 26.7 and 4.6% of patients reported
ADRs and serious ADRs, respectively. Table 2 also lists
selected important ADRs; various forms of pneumonia
were the most common ADR (n = 174, 1.3%). Tubercu-
losis was reported as an ADR in 12 patients (0.1%), and
interstitial lung disease in 81 patients (0.6%). No cases of
demyelinating disease were observed. Lupus-like syn-
drome and congestive heart failure (including all heart
failure) were recorded as ADRs in 5 and 7 patients,
respectively. Thirty cases of malignancy were reported
(0.2%), and there were 76 deaths (0.6%) during the
24-week study.
Risk factors for the development of serious infections
are shown in Table 3. Compared with the respective ref-
erent group, female sex and concomitant methotrexate use
signiﬁcantly lowered the risk of infection, whereas older
age (C65 years), history of infectious disease, presence of
any comorbidities, Steinbrocker functional class 4, and
concomitant glucocorticoid use signiﬁcantly increased
serious infection risk. Prior history of tuberculosis slightly,
but not signiﬁcantly, raised the infection risk compared
Table 1 Patient demographics
Characteristic Male
patients
(n = 2580)
Female
patients
(n = 11,314)
p value
a
Mean (SD) age, years 57.5 (13.2) 60.7 (12.4) \0.001
b
Age range [n (%), years]
\20 11 (0.4) 65 (0.6)
20–29 52 (2.0) 342 (3.0)
30–39 124 (4.8) 843 (7.5)
40–49 198 (7.7) 1382 (12.2)
50–59 691 (26.8) 3243 (28.7)
60–69 837 (32.4) 3358 (29.7)
C70 667 (25.9) 2081 (18.4) \0.001
Mean (SD) weight, kg 61.7 (10.4) 51.3 (9.0) \0.001
b
Disease duration [n (%), years]
\2 436 (16.9) 1168 (10.3)
2–\5 588 (22.8) 1844 (16.3)
5–\10 589 (22.8) 2386 (21.1)
10–\15 328 (12.7) 1925 (17.0)
15–\20 194 (7.5) 1166 (10.3)
C20 208 (8.1) 1795 (15.9)
Unknown (years) 237 (9.2) 1030 (9.1) \0.001
Steinbrocker stage [n (%)]
I 241 (9.4) 624 (5.5)
II 801 (31.1) 2458 (21.7)
III 928 (36.0) 3998 (35.4)
IV 606 (23.5) 4225 (37.4) \0.001
Steinbrocker class [n (%)]
1 277 (10.8) 946 (8.4)
2 1536 (59.6) 6526 (57.7)
3 694 (26.9) 3482 (30.8)
4 69 (2.7) 351 (3.1) \0.001
Positive history of concomitant
medical conditions [n (%)]
987 (38.8) 3079 (27.6) \0.001
Tuberculosis 228 (8.8) 649 (5.7) \0.001
Interstitial pneumonitis 341 (13.2) 693 (6.1) \0.001
Follicular bronchitis 5 (0.2) 32 (0.3)
COPD 43 (1.7) 41 (0.4) \0.001
Total comorbidities [n (%)] 1570 (60.9) 6359 (56.2) \0.001
Hepatic 155 (6.0) 475 (4.2) \0.001
Renal 152 (5.9) 395 (3.5) \0.001
Hematologic 100 (3.9) 698 (6.2) \0.001
Cardiac 217 (8.4) 569 (5.0) \0.001
Infectious (nonserious) 56 (2.2) 168 (1.5) 0.013
Diabetes mellitus 340 (13.2) 758 (6.7) \0.001
Weekly etanercept dose regimen [n (%), mg]
50 2018 (78.2) 8560 (75.7)
25 264 (10.2) 1298 (11.5)
20 2 (0.1) 27 (0.2)
20–50
c 296 (11.5) 1429 (12.6) 0.023
d
Table 1 continued
Characteristic Male
patients
(n = 2580)
Female
patients
(n = 11,314)
p value
a
Concomitant DMARD/
biologic use [n (%)]
1924 (74.6) 8352 (73.8)
Prior glucocorticoid use
[n (%)]
e
2209 (88.4) 9378 (85.5) \0.001
Concomitant MTX use [n (%)] 1371 (53.1) 6397 (56.5) 0.002
MTX dose [n (%), mg/week]
0–\4 39 (2.8) 271 (4.2)
4–\6 239 (17.4) 1583 (24.7)
6–\8 448 (32.7) 2157 (33.7)
8–\10 497 (36.3) 1898 (29.7)
C10 148 (10.8) 488 (7.6) \0.001
Prior inﬂiximab use [n (%)] 366 (14.2) 1512 (13.4)
COPD chronic obstructive pulmonary disease, DMARD disease-
modifying antirheumatic drug, MTX methotrexate
a The p values indicated are for comparisons between male and
female patient data, using v
2tests unless otherwise indicated
b Comparisons were made using the t-test
c Patients received variable dosing during the observation period
d Comparisons were made using Fisher exact test
e Unknown patients were omitted from the percentage calculation
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Model 2 showed the combined effects of multiple risk
factors on the occurrence of serious infections adjusted for
the remaining variables included in model 1. Compared
with patients without combined risk factors, the hazard
ratio of serious infection was 9.91 (95% CI 5.48–17.94;
p\0.001) for patients who had 3 risk factors, 4.24 (95%
CI 2.83–6.34; p\0.001) for patients who had 2 risk fac-
tors, and 1.96 (95% CI 1.30–2.96; p = 0.001) for patients
who had 1 risk factor. Highly signiﬁcant linear association
(p\0.001) was evident for increasing number of com-
bined risk factors.
Effectiveness
The effectiveness of etanercept treatment as determined by
various assessment methods is shown in Table 4. The mean
DAS28 decreased signiﬁcantly (both p\0.01), from 5.9 at
baselineto4.3atweek4(27%improvement)and3.8atweek
24 (36% improvement). The mean duration of morning
stiffness also decreased signiﬁcantly (both p\0.01), from
111.3 min at baseline to 44.2 min at week 4 (60%
improvement)and31.1 minatweek24(72%improvement).
The mean numbers of tender joints (9.2 at baseline, 4.2 at
week 4, and 3.0 at week 24) and swollen joints (8.6, 4.1, and
2.8, respectively), and the mean general health status (60.1,
36.6, and 30.7 mm, respectively, by patients’ visual analog
scale) all showed signiﬁcant (all p\0.01) improvements
from baseline at weeks 4 and 24. The mean ESR improved
signiﬁcantly, from 58.7 mm/h (baseline) to 38.1 mm/h
(week 4) and 34.8 mm/h (week 24), representing improve-
ments of 35 and 41%, respectively (both p\0.01). The
mean levels of CRP decreased signiﬁcantly (both p\0.01),
from 3.6 mg/dL at baseline to 1.4 mg/dL at week 4 (61%
improvement) and 1.2 mg/dL at week 24 (67%
improvement).
The EULAR response and DAS28 remission rate were
alsoevaluated.Atweek4,779patients(17.6%)hadachieved
agoodEULARresponse;atrendofsigniﬁcantimprovement
occurred throughout the observation period, with 2336
patients (31.6%) having a good response by week 24
(p\0.001 for trend; Fig. 1a). At week 4, 77.0% of patients
had achieved a good or moderate response; response rates
increased from week 4 to 24, with 84.3% of patients
achievingagoodormoderateresponsebyweek24.Atotalof
1161 (15.7%) patients hadno response toetanercept atweek
24 (Fig. 1a). Remission was reported in 1395 patients
(18.9%) at week 24, with signiﬁcant improvement noted
duringthe observationperiod(p\0.001fortrend;Fig. 1b).
Low, moderate, and high disease activity were reported in
1179 (15.9%), 3730 (50.4%), and 1091 (14.8%) patients,
respectively, at week 24 (Fig. 1b).
Factors that affected the odds of achieving RA remission
are shown in Table 5. Compared with the referent group in
model 1, male sex, younger age (\65 years), concomitant
methotrexate use, lower baseline DAS28 (moderate
Table 2 Incidences of the most commonly reported adverse events,
serious adverse events, important adverse drug reactions, and death
Event n (%)
Patients with at least 1 AE,
a total 4336 (31.2)
Injection site reaction 610 (4.4)
Rash 339 (2.4)
Abnormal hepatic function 328 (2.4)
Nasopharyngitis 288 (2.1)
Pyrexia 261 (1.9)
Upper respiratory tract infection 224 (1.6)
Pruritus 202 (1.5)
Total pneumonia
b 189 (1.0)
Herpes zoster 115 (0.8)
Erythema 114 (0.8)
Patients with at least 1 SAE,
a total 857 (6.2)
Total pneumonia
b 116 (0.8)
Interstitial lung disease 77 (0.6)
Pyrexia 40 (0.3)
Sepsis 27 (0.2)
Herpes zoster 23 (0.2)
Pneumocystis jiroveci pneumonia 24 (0.2)
Urinary tract infection 16 (0.1)
Abnormal hepatic function 15 (0.1)
Bacterial arthritis 13 (0.1)
Bronchitis 13 (0.1)
Patients with at least 1 important ADR
a 968 (7.0)
c
Total pneumonia
b 174 (1.3)
Interstitial lung disease 81 (0.6)
Pneumocystis jiroveci pneumonia 25 (0.2)
Malignancy 30 (0.2)
Tuberculosis
d 12 (0.1)
Pulmonary 10 (0.1)
Extrapulmonary 3 (\0.1)
Congestive heart failure 7 (0.1)
Lupus-like syndrome 5 (\0.1)
Demyelinating disease 0 (0)
Deaths 76 (0.6)
ADR adverse drug reaction, AE adverse event, SAE serious adverse
event
a Patients who had at least 1 AE, SAE, or speciﬁcally important
ADR, respectively. The 10 most frequently reported AEs, SAEs, and
ADRs are listed
b Total pneumonia = pneumonia ? bacterial pneumonia ? bron-
chopneumonia ? Chlamydia pneumonia ? staphylococcal pneumo-
nia ? Candida pneumonia ? fungal pneumonia; 1 patient developed
both pneumonia and bronchopneumonia
c 609 patients who had injection site reactions were included
d 1 patient had both pulmonary and extrapulmonary tuberculosis
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signiﬁcantly improved the odds of achieving remission.
Shorter duration of RA also signiﬁcantly improved the
chances of achieving remission compared with those with
C15 years’ duration (odds ratio [OR] 1.62; 95% CI
1.36–1.92). Model 2 showed the combined effects of
multiple risk factors on the likelihood of achieving remis-
sion. Compared with the groups with zero risk factors, the
odds ratio of achieving remission was 6.30 (95% CI
4.83–8.21; p\0.001) for patients who had 4 risk factors,
3.20 (95% CI 2.64–3.88; P\0.001) for patients who had 3
risk factors, and 1.87 (95% CI 1.55–2.26; p\0.001) for
patients who had 2 risk factors. Highly signiﬁcant linear
association (p\0.001) was evident for increasing number
of combined risk factors. When we added 79 patients with
lower disease activity (baseline DAS28, C2.6 and B3.2)
Table 3 Hazard ratios for serious infection (adverse events)
Variable HR 95% CI p value
Model 1
a
Sex (women vs. men) 0.63 0.50–0.81 \0.001
Age (C65 vs.\65 years of age) 1.66 1.33–2.07 \0.001
History of infectious disease (yes vs. no) 2.26 1.38–3.70 0.001
History of tuberculosis (yes vs. no) 1.24 0.85–1.80 0.274
Presence of any comorbidities (yes vs. no) 2.72 2.02–3.66 \0.001
Steinbrocker functional class (4 vs. 1 ? 2 ? 3) 2.54 1.73–3.71 \0.001
Duration of RA (years)
C5 and\10 vs.\5 1.20 0.89–1.61 0.237
C10 and\15 vs.\5 1.01 0.72–1.41 0.971
C15 vs.\5 1.04 0.78–1.40 0.774
Concomitant use of MTX (yes vs. no) 0.59 0.47–0.74 \0.001
Concomitant use of glucocorticoids (yes vs. no) 2.03 1.46–2.84 \0.001
Model 2
b
Presence of combined risk factors
c
1 vs. 0 1.96 1.30–2.96 0.001
2 vs. 0 4.24 2.83–6.34 \0.001
3 vs. 0 9.91 5.48–17.94 \0.001
HR hazard ratio, CI conﬁdence interval, MTX methotrexate
a Cox proportional hazard model (for all cases, n = 12,620 and for serious infection cases, n = 330)
b Results were adjusted for sex, age, history of infectious disease, history of tuberculosis, duration of rheumatoid arthritis (RA), and concomitant
use of glucocorticoid
c Combined factors: Steinbrocker functional class = 4, concomitant use of MTX = no, any comorbidities = yes; p\0.001 for linear trend
using the Wald test
Table 4 Measures of effectiveness
Measure Baseline,
mean (SD)
Patients evaluated
at baseline (n)
Week 4,
mean (SD)
a
Patients evaluated
at week 4 (n)
Week 24,
mean (SD)
a
Patients evaluated
at week 24 (n)
DAS28 5.9 (1.2) 8902 4.3 (1.3) 4754 3.8 (1.3) 8137
Duration of morning stiffness (min) 111.3 (181.3) 5858 44.2 (114.0) 3201 31.1 (90.1) 5058
Tender joints (n) 9.2 (7.0) 12727 4.2 (4.8) 7873 3.0 (4.1) 12321
Swollen joints (n) 8.6 (6.2) 12727 4.1 (4.3) 7871 2.8 (3.6) 12319
General health status
(patient visual analog scale) (mm)
60.1 (22.7) 11535 36.6 (22.5) 6702 30.7 (22.1) 10616
ESR (mm/h) 58.7 (33.0) 9719 38.1 (27.7) 5732 34.8 (27.5) 9484
CRP (mg/dL) 3.6 (3.3) 12693 1.4 (2.1) 8298 1.2 (2.0) 12770
CRP C-reactive protein, DAS28 modiﬁed disease activity score including a 28-joint count, ESR erythrocyte sedimentation rate
a All comparisons differed signiﬁcantly (p\0.01 vs. baseline), by t-test
348 Mod Rheumatol (2011) 21:343–351
123into the lower baseline DAS28 group to examine the odds
ratio of achieving remission, a similar pattern was seen
(data not shown).
Discussion
The current trial was one of the largest surveillance studies
of biologic use in the rheumatology area, with nearly
14,000 patients registered. Mandatory registration for all
patients treated with etanercept occurred at participating
sites in Japan during the 2-year study period. This PMS
study provided a unique opportunity to capture real-world
safety and effectiveness data for a large patient population
in an Asian country. Although there are published accounts
of other PMS studies with RA biologic treatments [23–25],
the large number of patients registered in the current study
allowed for the safety and effectiveness of etanercept to be
documented in a real-world clinical setting in Japan. The
advantage of conducting a study like this is a high precision
of AE incidence, remission rate, and other important data.
In the current PMS study, AEs and SAEs were reported
in 31.2 and 6.2% of patients, respectively. A good or
moderate response (i.e., effective treatment) occurred in a
very high percentage of patients from week 4 to 24. These
data are consistent with those reported in the interim
analysis from this study [17]. No new signaling risk factors
for serious infection were observed in this PMS study.
Real-world efﬁcacy data were also reported from the
Rheumatoid Arthritis DMARD Intervention and Utilization
Study (RADIUS), a 5-year, multicenter, observational
Fig. 1 Time course of a EULAR response and b DAS28 from week 4
to week 24. DAS28 modiﬁed disease activity score including a
28-joint count, EULAR European League Against Rheumatism.
Cochran-Armitage tests were used to examine evidence of trends in
response rates; trends for good response rate and remission rate were
statistically signiﬁcant (p\0.001). wk Week
Table 5 Odds ratios for achieving remission
Variable OR 95% CI p value
Model 1
Sex (men vs. women) 1.30 1.10–1.53 0.002
Age (\65 vs. C65 years of age) 1.43 1.23–1.65 \0.001
Steinbrocker functional class (1–3 vs. 4) 2.41 1.30–4.49 0.006
Duration of RA (years)
\5 vs. C15 1.62 1.36–1.92 \0.001
5–10 vs. C15 1.17 0.97–1.42 0.098
10–15 vs. C15 1.04 0.84–1.28 0.733
DAS28 at baseline (moderate vs. high) 2.95 2.59–3.37 \0.001
Concomitant use of MTX
\8 mg/week vs. none 1.30 1.13–1.49 \0.001
C8 mg/week vs. none 1.74 1.32–2.28 \0.001
Previous treatment with inﬂiximab
(yes vs. no)
0.65 0.53–0.81 \0.001
Model 2
a
Presence of combined risk factors
b
4 vs. 0–1 6.30 4.83–8.21 \0.001
3 vs. 0–1 3.20 2.64–3.88 \0.001
2 vs. 0–1 1.87 1.55–2.26 \0.001
Multiple logistic regression models [for all cases, n = 6763 (79
patients with low disease activity were excluded) and for remission
cases, n = 1234]
DAS28 modiﬁed disease activity score including a 28-joint count,
MTX methotrexate, OR odds ratio, RA rheumatoid arthritis
a Results were adjusted for sex, age, and previous treatment with
inﬂiximab
b Combined factors: Steinbrocker functional class = 1–3; MTX =
yes; baseline DAS28 =[3.2 and B5.1 (moderate disease); duration of
RA\5 years; p\0.001 for linear trend using the Wald test
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therapies in the United States (N = 10,061 in 2 cohorts)
[26, 27]. Although safety data have not yet been reported,
patients treated with etanercept, with (p\0.01) or without
(p\0.05) methotrexate, were signiﬁcantly more likely to
have a modiﬁed ACR 20% response at 12 months com-
pared with those receiving only methotrexate. In another
PMS study involving TNF-a antagonists, Feltelius et al.
[23] collected safety and effectiveness data from 1999 to
2003 in the cohort of all etanercept-treated Swedish
patients with RA (N = 1073). The 24-month incidence
rates of ADRs and SAEs of 27 and 7%, respectively, in that
study are both similar to those observed in the current PMS
study. A good or moderate EULAR response rate was
observed in 86% of 517 patients, which is similar to the
rate reported in our analysis (84.3%) at week 24.
Because the registered patients in the current PMS study
had varied backgrounds, multivariate analyses were con-
ducted to ascertain risk factors related to safety and
effectiveness in a real-world setting. The current PMS
study identiﬁed several factors that improved the safety and
effectiveness outcomes of patients treated with etanercept.
Patients were more likely to achieve DAS28 remission if
they had moderate disease activity, better Steinbrocker
functional class, shorter disease duration, and received
concomitant methotrexate treatment. Importantly, patients
who had a combination of these factors showed a higher
probability of achieving remission.
Cox proportional hazard model results also demon-
strated several risk factors for serious infection. A combi-
nation of Steinbrocker functional class 4, no use of
concomitant methotrexate, and the presence of any
comorbidities signiﬁcantly increased the risk for develop-
ing serious infection. Thus, the combined use of etanercept
and methotrexate in patients with early moderate RA with
less comorbidity and better physical function appears to
provide patient beneﬁt for the achievement of remission
and lowering of SAE occurrences.
Interpretationofthesedataissomewhatlimitedbythefact
that no control arm was included in this large PMS study.
This makes it difﬁcult to distinguish outcomes relating to
etanercepttreatmentfromthosecausedbyotherfactors(e.g.,
patient expectations, natural history of the disease, or con-
comitant treatments). The study length (6 months) allowed
for the collection of important safety and effectiveness data,
but longer-term studies would also be useful. Additionally,
evaluations of effectiveness did not include radiographic
analysis to conﬁrm the effectiveness of treatment.
This PMS study collected safety and effectiveness data
for every Japanese patient with RA receiving etanercept at
the participating study sites for a 2-year period. With
nearly 14,000 patients registered, this represents one of the
largest observational surveillance studies conducted to date
in RA patients treated with biologics. The safety and
effectiveness data reported here support data from previous
clinical trials with etanercept and are also consistent with
the data from the interim analysis of this study. Additional
subgroup analyses from this study may enable the identi-
ﬁcation of important factors affecting the safety and
effectiveness of etanercept so that treatment decisions can
be further optimized.
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